REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: China Threatens Retaliation Over Hong Kong Bill

Thu, 21st Nov 2019 12:03

(Alliance News) - Stock prices in London were lower at midday on Thursday after US lawmakers passed a bill supporting Hong Kong's rights, potentially putting US-China trade progress in jeopardy.

US lawmakers took the last step to approve legislation supporting protesters in Hong Kong in an almost unanimous vote on Wednesday, before sending it on to President Donald Trump for a signature.

China on Thursday accused the US of seeking to "destroy" Hong Kong and threatened retaliation after Congress passed new legislation supporting the pro-democracy movement that has thrown the city into nearly six months of turmoil.

Foreign Minister Wang Yi said the passage of the Hong Kong Human Rights & Democracy Act "indulges violent criminals" which China blames for the worsening unrest and aims to "muddle or even destroy Hong Kong".

In addition, a foreign ministry spokesman vowed that China would "take effective measures to resolutely fight back", giving no details.

The FTSE 100 was down 48.62 points, or 0.7%, at 7,213.87. The FTSE 250 was down 152.57 points, or 0.8%, at 20,322.68, but the AIM All-Share was up 1.42 points, or 0.1%, at 900.74.

The Cboe UK 100 index was down 0.6% at 12,236.62. The Cboe UK 250 was down 0.8% at 18,262.07, and the Cboe UK Small Companies was flat at 11,313.71.

In Paris the CAC 40 was down 0.3%, while the DAX 30 in Frankfurt was down 0.2%.

"Trump's likely signing of the Hong Kong bill raises the prospect that the US and China will find something other than trade to quarrel over - if the president was looking for an excuse to renew their trade spat then he has a tailor-made opportunity here to both hit China on trade and present himself as a champion of human rights and democracy. For someone so devoted to his public image, especially now the impeachment hearings are piling on the pressure, the opportunity may be too big to pass up," said IG Group's Chris Beauchamp.

On the London Stock Exchange, Centrica was the best blue-chip performer, up 8.0% after the British Gas owner backed annual guidance after what it said has been a "solid" second-half performance.

The utility delivered growth in customer accounts, higher margins, and returns in business energy supply in North America, it said, as well as strong trading in Europe. This has helped offset the impact of further outages at the non-operated Dungeness B and Hunterston B nuclear power stations, in Kent and North Ayrshire respectively. Nuclear operations were put up for sale earlier this year.

Centrica backed 2019 guidance of adjusted operating cash flow at the lower end of GBP1.8 billion to GBP2.0 billion, and net debt within GBP3.0 billion to GBP3.5 billion. The firm has cut capital investment guidance to GBP800 million from GBP900 million, and increased efficiency savings for the year to GBP300 million from GBP250 million.

GlaxoSmithKline was up 0.9% after UBS raised the drugmaker to Buy from Neutral.

At the other end of the large-cap index. Johnson Matthey was down 7.5% after the specialty chemical firm said interim profit was hit by problems in its Clean Air division.

Pretax profit fell 8% to GBP225 million for the half-year to September, and the underlying figure also declined by 8% to GBP231 million. The company said profit was hit by around GBP15 million of one-off costs in the Clean Air division due to higher freight costs and manufacturing inefficiencies. This, Johnson Matthey continued, stemmed from the phasing of the completion of a new plant in Poland.

Looking ahead, Johnson Matthey expects full-year performance to meet the market's expectations.

Aviva was down 1.8% after Deutsche Bank cut the insurer to Hold from Buy.

In the FTSE 250, Direct Line Insurance was the best performer, up 6.0% after the insurer late Wednesday said its third-quarter performance was encouraging.

Direct Line said its total gross written premiums for the three months to September 30 rose 0.4% to GBP858.0 million from GBP854.5 million the year before. This included a return to growth for motor to GBP457.8 million, up 0.3% from GBP456.4 million.

In terms of financial targets, Direct Line is aiming to improve its operating expense ratio to 20% by the end of 2023 so it is more sustainably competitive. In 2018, Direct Line's operating expenses came to GBP722 million, or GBP644 million before depreciation and amortisation. The company hopes to cut this GBP644 figure by over GBP50 million by 2021 to under GBP590 million.

Further, Direct Line gave details on plans for capital returns saying: "At the group's current valuation, where the regular dividend yield is materially higher than market comparators, the board's preference is to return any surplus capital, after ordinary dividends, by way of a buyback programme."

At the other end of the midcaps, Royal Mail was by far the worst performer, down 16%. The postal operator reported a significant rise in interim profit, but warned its transformation plan is off track.

Royal Mail's pretax profit for the six months to September 29 multiplied to GBP173 million from GBP33 million, though the adjusted figure was down 20% to GBP146 million. Revenue climbed by 5.2% to GBP5.17 billion.

However, Royal Mail warned the outlook for the letters business in the UK remains challenging, due to lower-than-expected UK economic growth and business uncertainty. For its current financial year, Royal Mail sees a 7% to 9% fall in addressed letter volumes, excluding the upcoming UK general election, which brings a surge of political mailings. Next year, volumes could fall between 6% to 8%.

"Royal Mail's investment case always rested heavily on the argument that years of public ownership had left the group bloated, underinvested and with lots of low hanging efficiency savings to harvest. Well that may have been true up to a point, but any low hanging fruit is long gone, and a heavily unionised workforce is making future cost savings difficult, if not impossible, to deliver. The combination of falling revenues and stubbornly high costs is stamping out the group's profit margins," commented Hargreaves Lansdown analyst Nick Hyett.

The pound was quoted at USD1.2645 at midday, up from USD1.2909 at the London equities close Wednesday, with three weeks to go until the UK general election.

On the UK political front, opposition party Labour said its manifesto would bring about "real change" to overhaul the UK's "rigged" society as it pledged to boost wages, tackle climate change and re-nationalise key utilities.

Leader Jeremy Corbyn revealed the full details of his election manifesto in a speech in Birmingham. It includes promises of free broadband for all homes and businesses by 2030 and more money for the health service.

On Brexit, the party will keep to the position decided at its autumn conference of renegotiating an exit deal with the EU by March and then putting those terms to a public vote within another three months, with Remain as an option.

The manifesto will contain intentions to significantly boost NHS spending, create a GBP10 minimum hourly wage for all, and tackle climate change by creating jobs in a "green industrial revolution".

Stocks in New York were set for a lower open with the DJIA, S&P 500 index and Nasdaq Composite all pointed down 0.1%.

US central bankers last month dismissed the idea of taking interest rates into negative territory, according to meeting minutes released on Wednesday.

Evidence for the benefits of negative interest rates - lenders must pay borrowers rather than the other way around - has proven "mixed" in countries where it has been tried, according to members of the Fed's rate-setting Federal Open Market Committee.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

London market Midday is available to subscribers as an email newsletter. Contact info@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.